Vir Biotechnology (VIR) Enterprise Value (2018 - 2026)
Vir Biotechnology recorded quarterly Enterprise Value of -$470.4 million in Q1 2026, down 2.06% quarter-over-quarter from -$460.9 million in Q4 2025, and down 65.48% year-over-year from -$1.4 billion in Q1 2025.
Vir Biotechnology's Enterprise Value history runs 9 years deep, the most recent figure standing at -$470.4 million for Q1 2026.
- In Q1 2026, Enterprise Value fell 65.48% year-over-year to -$470.4 million; the TTM figure through Mar 2026 stood at -$470.4 million (down 65.48% YoY), while the FY2025 annual figure was -$460.9 million, up 39.94% from the prior year.
- Enterprise Value came in at -$470.4 million for Q1 2026 at Vir Biotechnology, down from -$460.9 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$95.1 million in Q3 2024 to a low of -$2.4 billion in Q4 2022.
- A 5-year average of -$937.8 million and a median of -$767.4 million in 2024 frame the typical range for Enterprise Value.
- Across the five-year window, Enterprise Value slumped 949.78% in 2022 and jumped 92.37% in 2024, its largest moves.
- Vir Biotechnology's Enterprise Value stood at -$2.4 billion in 2022, then surged by 89.39% to -$251.4 million in 2023, then slumped by 205.23% to -$767.4 million in 2024, then jumped by 39.94% to -$460.9 million in 2025, then declined by 2.06% to -$470.4 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$470.4 million, -$460.9 million, and -$178.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.32 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -3.01 Bn |
| 10 | Vir Biotechnology | 1.33 Bn | 1.33 Bn | - | -470.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -470.44 Mn |
| Dec 31, 2025 | -460.94 Mn |
| Sep 30, 2025 | -178.76 Mn |
| Jun 30, 2025 | -218.37 Mn |
| Mar 31, 2025 | -284.30 Mn |
| Dec 31, 2024 | -767.44 Mn |
| Sep 30, 2024 | -95.12 Mn |
| Jun 30, 2024 | -1.15 Bn |
| Mar 31, 2024 | -998.46 Mn |
| Dec 31, 2023 | -251.43 Mn |
| Sep 30, 2023 | -1.25 Bn |
| Jun 30, 2023 | -1.83 Bn |
| Mar 31, 2023 | -1.42 Bn |
| Dec 31, 2022 | -2.37 Bn |
| Sep 30, 2022 | -2.32 Bn |
| Jun 30, 2022 | -667.26 Mn |
| Mar 31, 2022 | -1.21 Bn |
| Dec 31, 2021 | -225.78 Mn |
| Sep 30, 2021 | -770.08 Mn |
| Jun 30, 2021 | -91.11 Mn |
| Mar 31, 2021 | -733.03 Mn |
| Dec 31, 2020 | -308.28 Mn |
| Sep 30, 2020 | -373.44 Mn |
| Jun 30, 2020 | -191.62 Mn |
| Mar 31, 2020 | -355.61 Mn |
| Dec 31, 2019 | -280.28 Mn |
| Sep 30, 2019 | -320.21 Mn |
| Jun 30, 2019 | -80.68 Mn |
| Mar 31, 2019 | -64.72 Mn |
| Dec 31, 2018 | -98.44 Mn |
| Sep 30, 2018 | -47.67 Mn |